Abdur Rehman is a Cardiology physician. OpenAlex indexes 56 publications with 884 citations (h-index 17); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
7677 Yankee St Ste 140
Centerville, OH 454593475
Telephone
937-454-9527Provider last certified this registry record 17 Mar 2026.
Clinical trials
- Efficacy of Milrinone With Sildenafil in Persistent Pulmonary Hypertension in Children
Sponsor: Muhammad Aamir Latif
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- W. L. Gore & Associates, Inc.Program year20251 payment
- Stryker CorporationProgram year20251 payment
- Boston Scientific CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.2%Beta blocker24.8%Metoprolol Succinate83%Carvedilol17%Part D≥145 patientsStatin13.3%Atorvastatin Calcium76%Rosuvastatin Calcium24%Part D≥86 patients+ 11 more classes in this area
Blood & clotting
16.9%P2Y12 inhibitor10.1%Clopidogrel82%Prasugrel Hcl13%Brilinta5%Part D<11 patientsFactor Xa inhibitor6.8%Eliquis89%Xarelto11%Part D<11 patientsMetabolism & gastrointestinal
3%SGLT2 inhibitor3%Farxiga55%Jardiance45%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- THE ROLE OF ARTIFICIAL INTELLIGENCE IN PUBLIC HEALTH SURVEILLANCE: A POST-PANDEMIC PERSPECTIVE
Insights-Journal of Life and Social Sciences
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”